Synamics Therapeutics develops AI-driven therapies that predict and counteract drug resistance in cancer treatment. Their proprietary platform, Dynaptive, designs compounds that maintain efficacy against evolving tumors, ensuring patients have access to effective oncology medicines.
Funding
Funding not disclosed
Founders
Product
Problem
Cancer cells frequently develop resistance to drug therapies, rendering treatments ineffective over time. This resistance necessitates the development of new drugs and treatment strategies to combat evolving tumors.
Solution
Synamics Therapeutics is developing AI-driven therapies to predict and counteract drug resistance in cancer treatment. Their Dynaptive platform uses advanced AI to model and predict how tumors will evolve and resist treatment. By designing compounds that preemptively overcome resistance mechanisms, Synamics aims to ensure the prolonged effectiveness of oncology medicines. This approach seeks to deliver enduring, life-saving therapies by anticipating cancer's next move.
Target Audience
The primary target audience includes cancer patients, oncologists, and pharmaceutical companies seeking more effective and durable cancer treatments.
Features
- Dynaptive platform uses AI to model and predict drug resistance mechanisms in cancer cells.
- Designs compounds that preemptively overcome resistance, maintaining efficacy against evolving tumors.
- Aims to deliver enduring, life-saving therapies by anticipating cancer's evolution.